The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial

BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the standard of care after coronary stenting, including coronary stenting involving bioresorbable scaffolds (BRSs). Current clinical guidelines recommend at least 12 months of DAPT after BRS implantation. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yizhe, Yin, Jiasheng, Li, Chenguang, Zhang, Wei, Shen, Li, Ge, Lei, Qian, Juying, Ge, Junbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854195/
https://www.ncbi.nlm.nih.gov/pubmed/36670441
http://dx.doi.org/10.1186/s13063-022-07028-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854195/
https://www.ncbi.nlm.nih.gov/pubmed/36670441
http://dx.doi.org/10.1186/s13063-022-07028-8

Ejemplares similares